To obtain definitive validation, we finally examined by ddPCR for KRAS codon 12/13 and 61 mutations, as well as TP53 CNA, additional six MPM‐associated MPE samples from Nantes (Gueugnon et al, 2011; Smeele et al, 2018) and 17 MPM tumor samples from Istanbul, Turkey (patients' clinical characteristics are given in Appendix Table S3). This evidence concerns the gene KRAS and neoplasm.